|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to a study on the side effects, adverse reactions, |
|
including death, and the effectiveness of vaccines against the |
|
SARS-CoV-2 virus (COVID-19) or its variants. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. (a) In this section: |
|
1) "Commission" means the Health and Human Services |
|
Commission. |
|
2) "Executive commissioner" means the executive commissioner |
|
of the Health and Human Services Commission. |
|
3) "Department" means the Department of State Health |
|
Services. |
|
4) "COVID-19" means the SARS-CoV-2 virus and any of its |
|
variants. |
|
5) "Vaccine" means a substance used to stimulate immunity to |
|
a particular infectious disease or pathogen, typically prepared |
|
from an inactivated or weakened form of the causative agent or from |
|
its constituents or products. |
|
(b) The Commission in collaboration with the Department shall |
|
conduct a study to assess the full and complete adverse reactions, |
|
including death, and effectiveness of each type of vaccine used in |
|
Texas to defend the human body against "COVID-19. The Report must |
|
include: |
|
1) The immediate short-term side effects and adverse |
|
reactions recipients experienced from taking the various COVID-19 |
|
vaccines used in Texas; including but not limited to include: |
|
i. Pain, swelling, or redness where the shot was given |
|
ii. Mild fever |
|
iii. Chills |
|
iv. Feeling tired |
|
v. Headache |
|
vi. Muscle and joint aches |
|
2) The immediate serious side effects and adverse reactions |
|
recipients experienced from taking the various COVID-19 vaccines |
|
used in Texas; including but not limited to include: |
|
i. difficulty breathing; |
|
ii. swelling of the face and throat; |
|
iii. accelerated heartbeat; |
|
iv. a body rash; |
|
v. dizziness; and |
|
vi. weakness |
|
3) Any long-term side effects and adverse reactions |
|
recipients have experienced from taking the various COVID-19 |
|
vaccines used in Texas; including but not limited to include: |
|
i. paralysis; |
|
ii. Myocarditis; |
|
iii. clotting disorders; |
|
iv. Thrombosis with Thrombocytopenia Syndrome (TTS); |
|
v. Guillain-Barré syndrome (GBS); |
|
vi. difficulty thinking or "brain fog," |
|
vii. chronic pain; |
|
viii. tiredness and fatigue; |
|
ix. loss of taste; |
|
x. depression; |
|
xi. anxiety; and |
|
xii. death. |
|
4) Any misrepresentations about the effectiveness or |
|
dangers of taking of the vaccine by its manufacturers or any |
|
governmental agency; and, |
|
5) Any concealment of information about the |
|
effectiveness or dangers of taking of the vaccine by its |
|
manufacturers or any governmental agency. |
|
(c) The Commission and the Department shall gather information for |
|
the report from: |
|
1) information collected by the Commission and the |
|
Department, including information from the department's vital |
|
statistics unit and the state Medicaid program; |
|
2) hospitals, treatment centers, available surveys; and |
|
3) and other relevant sources. |
|
SECTION 2. (a) Not later than January 1, 2024, the Commission and |
|
Department shall prepare and submit to the Governor, Lieutenant |
|
Governor, the Speaker of the House of Representatives, and the |
|
Chairpersons of the relevant Texas legislative committees with |
|
jurisdiction over the Commission and the Department, a copy of the |
|
report, summary of any findings, and any recommendations for |
|
legislative or executive action to reduce the prevalence of |
|
COVID-19 Vaccine side effects. The department may post the report |
|
on the department's Internet website. |
|
(b) The Commission and Department may accept gifts, grants, |
|
and donations from any source to fund expenses |
|
incurred by the Commission and the Department in |
|
preparing the report. |
|
SECTION 3. This Act expires September 1, 2025. |
|
SECTION 4. This Act takes effect immediately if it receives a vote |
|
of two-thirds of all the members elected to each house, as provided |
|
by Section 39, Article III, Texas Constitution. If this Act does |
|
not receive the vote necessary for immediate effect, this Act takes |
|
effect September 1, 2023. |